Piper Sandler Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Piper Sandler analyst Biren Amin maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and lowers the price target from $23 to $20.
Piper Sandler analyst Biren Amin maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and lowers the price target from $23 to $20.